Literature DB >> 29710213

Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis.

Jiraporn Jitprapaikulsan1,2, A Sebastian Lopez Chiriboga1, Eoin P Flanagan1,3, James P Fryer2, Andrew McKeon1,2,3, Brian G Weinshenker1,3, Sean J Pittock1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29710213      PMCID： PMC5933459          DOI： 10.1001/jamaneurol.2018.0805

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  6 in total

1.  Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients.

Authors:  Eoin P Flanagan; Shannon R Hinson; Vanda A Lennon; Boyan Fang; Allen J Aksamit; P Pearse Morris; Eati Basal; Josephe A Honorat; Nora B Alfugham; Jenny J Linnoila; Brian G Weinshenker; Sean J Pittock; Andrew McKeon
Journal:  Ann Neurol       Date:  2017-02       Impact factor: 10.422

2.  Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications.

Authors:  Álvaro Cobo-Calvo; María Sepúlveda; Raphael Bernard-Valnet; Anne Ruiz; David Brassat; Sergio Martínez-Yélamos; Albert Saiz; Romain Marignier
Journal:  Mult Scler       Date:  2015-07-24       Impact factor: 6.312

3.  Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.

Authors:  John J Chen; W Oliver Tobin; Masoud Majed; Jiraporn Jitprapaikulsan; James P Fryer; Jacqueline A Leavitt; Eoin P Flanagan; Andrew McKeon; Sean J Pittock
Journal:  JAMA Ophthalmol       Date:  2018-04-01       Impact factor: 7.389

4.  Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis.

Authors:  Yujuan Jiao; James P Fryer; Vanda A Lennon; Andrew McKeon; Sarah M Jenkins; Carin Y Smith; Amy M L Quek; Brian G Weinshenker; Dean M Wingerchuk; Elizabeth A Shuster; Claudia F Lucchinetti; Sean J Pittock
Journal:  JAMA Neurol       Date:  2014-01       Impact factor: 18.302

5.  AQP4 autoantibody assay performance in clinical laboratory service.

Authors:  J P Fryer; V A Lennon; S J Pittock; S M Jenkins; P Fallier-Becker; S L Clardy; E Horta; E A Jedynak; C F Lucchinetti; E A Shuster; B G Weinshenker; D M Wingerchuk; A McKeon
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2014-05-22

6.  Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis.

Authors:  Boyan Fang; Andrew McKeon; Shannon R Hinson; Thomas J Kryzer; Sean J Pittock; Allen J Aksamit; Vanda A Lennon
Journal:  JAMA Neurol       Date:  2016-11-01       Impact factor: 18.302
  6 in total
  4 in total

Review 1.  Magnetic resonance imaging in immune-mediated myelopathies.

Authors:  M J Wendebourg; S Nagy; T Derfuss; K Parmar; R Schlaeger
Journal:  J Neurol       Date:  2019-01-29       Impact factor: 4.849

Review 2.  Myelin oligodendrocyte glycoprotein antibodies in neurological disease.

Authors:  Markus Reindl; Patrick Waters
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

3.  Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders.

Authors:  Jacqueline Palace; Dan-Yu Lin; Donglin Zeng; Masoud Majed; Liene Elsone; Shahd Hamid; Silvia Messina; Tatsuro Misu; Jessica Sagen; Daniel Whittam; Yoshiki Takai; Maria Isabel Leite; Brian Weinshenker; Philippe Cabre; Anu Jacob; Ichiro Nakashima; Kazuo Fujihara; Sean J Pittock
Journal:  Brain       Date:  2019-05-01       Impact factor: 13.501

4.  S1 guidelines "lumbar puncture and cerebrospinal fluid analysis" (abridged and translated version).

Authors:  H Tumani; H F Petereit; A Gerritzen; C C Gross; A Huss; S Isenmann; S Jesse; M Khalil; P Lewczuk; J Lewerenz; F Leypoldt; N Melzer; S G Meuth; M Otto; K Ruprecht; E Sindern; A Spreer; M Stangel; H Strik; M Uhr; J Vogelgsang; K-P Wandinger; T Weber; M Wick; B Wildemann; J Wiltfang; D Woitalla; I Zerr; T Zimmermann
Journal:  Neurol Res Pract       Date:  2020-03-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.